Haridwar Today

Xerostomia Treatment Market, Epidemiology, Emerging Therapies and Key Companies Working in the Domain During the Study Period (2018-30) in the 7MM

 Breaking News
  • No posts were found

Xerostomia Treatment Market, Epidemiology, Emerging Therapies and Key Companies Working in the Domain During the Study Period (2018-30) in the 7MM

May 12
12:31 2021
Xerostomia Treatment Market, Epidemiology, Emerging Therapies and Key Companies Working in the Domain During the Study Period (2018-30) in the 7MM

Xerostomia Market
The Xerostomia Report from DelveInsight provides an in-depth understanding of Xerostomia, historical and forecasted epidemiology, and Xerostomia market dynamics in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), as well as Japan.

The Xerostomia Report from DelveInsight provides an in-depth understanding of Xerostomia, historical and forecasted epidemiology, and Xerostomia market dynamics in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom), as well as Japan.

Key Highlights from the Xerostomia Market Report

  • According to Hahnel et al. (2014), the prevalence of Xerostomia was 16 percent (patients with XI scores 10) and hyposalivation was 31 percent (patients with induced salivary flow rate 0.7 ml/min).

  • According to Rech et al findings, the prevalence of Xerostomia, low induced salivary flow rate, and low at rest salivary flow rate were 338 (38.8%), 494 (56.6%), and 320 (36.7%), respectively.

  • Emerging therapies in the Xerostomia market are LBS020 (Lubris BioPharma), AAV-AQP1 (MeiraGTx), and others.

  • Major companies involved in Xerostomia are Lubris BioPharma, MeiraGTx, among others.

Request sample page @ Xerostomia Market

The Xerostomia market report covers existing clinical practices, new drugs, individual therapies’ market share, and current and forecasted Xerostomia market sizes in the 7MM (the United States, the EU5, Germany, Italy, Spain, and France), and Japan.

Xerostomia: Disease Overview

Xerostomia, defined as defined as dry mouth,  is caused by insufficient salivary secretion as a result of irregular salivary gland activity, which is referred to as “actual” Xerostomia; however, most patients with Xerostomia do not have objective symptoms of hyposalivation. Oral dryness despite normal salivary gland function is referred to as “symptomatic” Xerostomia or “pseudo” Xerostomia.

Xerostomia Epidemiology Segmentation

  • Xerostomia Total Prevalent Cases

  • Xerostomia Gender-Specific Prevalent Cases

  • Xerostomia Age-Specific Prevalent Cases

  • Xerostomia Diagnosed and Treatable Cases

Xerostomia Treatment Landscape

Current treatment options for Xerostomia are:

  • Topical Medications

  • Pilocarpine and Cevimeline

  • Sprays

  • Salivary Stimulants and Substitutes

Xerostomia Market

The demand of Xerostomia market will expand throughout the forecast period as new therapies like LBS020 and AAV-AQP1 by the major players like Lubris BioPharma and MeiraGTx are introduced and the patient pool grows.

To learn more visit, Xerostomia Market Size

Xerostomia Pipeline Therapies and Key Companies

  • LBS020: Lubris BioPharma

  • AAV-AQP1: MeiraGTx

Table of Contents

1.

Report Introduction

2.

Executive Summary

3.

Xerostomia Market Overview at a Glance

4.

Disease Background and Overview: Xerostomia

5.

Xerostomia: Case Reports

6.

Xerostomia: Epidemiology Methodology

7.

Xerostomia: Epidemiology and Patient Population

8.

Xerostomia: Country-Wise Epidemiology

9.

Xerostomia: Treatments & Medical Practices

10.

Xerostomia: Marketed Products

11.

Xerostomia: Emerging Therapies

12

Xerostomia Market Size

13.

7MM Xerostomia: Country-Wise Market Analysis

14.

Xerostomia: Market Drivers

15.

Xerostomia: Market Barriers

16.

SWOT Analysis

17.

Xerostomia: Market Access and Reimbursement

18.

Appendix

19.

Report Methodology

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

Get in touch with our Business executive @ Xerostomia Market Insights to know more 

Related Reports

Erosive Esophagitis Market

DelveInsight’s “Erosive Esophagitis (EE) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Erosive Esophagitis (EE) , historical and forecasted epidemiology as well as the Erosive Esophagitis (EE) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Recent Posts

Acute-on-Chronic Liver Failure Market to Witness Growth by 2032, Estimates DelveInsight | Grifols Therapeutics, Versantis AG, HepaStem

Read Full Article

Categories